Multiple Sclerosis is a chronic central nervous system disease that affects an estimated 400,000 people in the United States and 2.5 million people worldwide. Beta interferon products are commonly used to treat Multiple Sclerosis and have annual sales of about $6 billion. Most patients treated with beta interferon products administer the drug three times per week by injection. BBT-032, our lead long-acting beta interferon analog, is expected to require only once per week to once per month administration. BBT-032 has completed preclinical testing and is anticipated to enter human clinical trials in 2018.